MELVILLE, NY, April 14, 2015 – BioRestorative Therapies, Inc. ("BRT" or “the Company”) (OTCBB: BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, announced today that the Company has relocated its corporate, administrative and laboratory operations to Melville, Long Island, New York.
The Company had previously announced a relocation incentive program offered by New York State and Suffolk County that helped enable BRT to establish a new facility in New York for its corporate headquarters and cell biology laboratory. BRT has closed and vacated its former location in Jupiter, Florida, and has commenced operations at its new location.
In addition to consolidating corporate activities in one location, BRT has established a new laboratory facility allowing for increased capabilities for the further development of possible additional cell-based treatments, products and protocols, stem cell-related intellectual property and translational research applications. BRT intends to expand its laboratory to include a cGMP (current Good Manufacturing Practices) facility, within the new location, that will enable the Company to formulate brtxDISC™, the Company’s lead therapeutic product for its Disc/Spine program.
“We are very excited to start laboratory operations in our new facility to advance our research programs and begin preparations for the clinical phase of our Disc/Spine program,” commented Mark Weinreb, BioRestorative Therapies’ Chief Executive Officer. “We have begun speaking with many local medical, scientific and academic institutions, and look forward to establishing important collaborations and relationships on Long Island and in the Tri-State area.”
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops products and medical therapies using cell and tissue protocols, primarily involving adult stem cells, including:
• Disc/Spine Program: Our lead cell therapy candidate, brtxDISC™ (Disc Implanted Stem Cells), is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The treatment involves collecting a patient’s own stem cells, culturing and cryopreserving the cells, and then having a physician inject brtxDISC™ into the patient’s damaged disc in an outpatient procedure. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery.
• ThermoStem® Program: We are developing an allogeneic cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.